Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qiangxin decoction granules is a Traditional Chinese Medicine (TCM) herbal formulation developed by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is designed for the treatment of heart failure, specifically heart failure with preserved ejection fraction (HFpEF). The drug is administered as oral granules and is currently being evaluated in a multicenter, randomized, double-blind, placebo-controlled clinical trial (ChiCTR2400082425) in China. This trial assesses the efficacy of syndrome-matched TCM granule regimens, including Qiangxin, when added to standard medical therapy, focusing on outcomes such as heart failure rehospitalization, cardiovascular death, and symptom improvement. The study also explores plasma transcriptomic and metabolomic changes associated with the treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qiangxin decoction granules.